{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:38:21Z","timestamp":1781887101055,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,29]]},"DOI":"10.7759\/cureus.26430","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T16:43:07Z","timestamp":1656520987000},"source":"Crossref","is-referenced-by-count":10,"title":["Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Shaalina","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simranjit","family":"Singh Kahlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Sikandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Peddemul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedevi","family":"Tejovath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushbu K","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Rheumatoid arthritis: common questions about diagnosis and management","volume":"97","author":"Wasserman A","year":"2018","unstructured":"Wasserman A. Rheumatoid arthritis: common questions about diagnosis and management. Am Fam Physician. 2018, 97:455-62.","journal-title":"Am Fam Physician"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen MM","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW, et al.. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004, 50:380-6. 10.1002\/art.20018","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh JA","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, et al.. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012, 64:625-39. 10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta JA","year":"2008","unstructured":"Avi\u00f1a-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008, 59:1690-7. 10.1002\/art.24092","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063867","article-title":"What effects might anti-TNF\u03b1 treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF\u03b1 in cardiovascular pathophysiology","volume":"66","author":"Dixon WG","year":"2007","unstructured":"Dixon WG, Symmons DP. What effects might anti-TNF\u03b1 treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF\u03b1 in cardiovascular pathophysiology. Ann Rheum Dis. 2007, 66:1132-6. 10.1136\/ard.2006.063867","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \"high-grade\" systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar N","year":"2003","unstructured":"Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how \"high-grade\" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003, 108:2957-63. 10.1161\/01.CIR.0000099844.31524.05","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.7.1121","article-title":"Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs","volume":"9","author":"Avouac J","year":"2008","unstructured":"Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother. 2008, 9:1121-8. 10.1517\/14656566.9.7.1121","journal-title":"Expert Opin Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282fb03d8","article-title":"Biologics and heart failure in rheumatoid arthritis: are we any wiser?","volume":"20","author":"Danila MI","year":"2008","unstructured":"Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG. Biologics and heart failure in rheumatoid arthritis: are we any wiser?. Curr Opin Rheumatol. 2008, 20:327-33. 10.1097\/BOR.0b013e3282fb03d8","journal-title":"Curr Opin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis","volume":"41","author":"van Sijl AM","year":"2011","unstructured":"van Sijl AM, Peters MJ, Knol DL, et al.. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum. 2011, 41:393-400. 10.1016\/j.semarthrit.2011.04.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21333","article-title":"High-intensity interval training among heart failure patients and heart transplant recipients: a systematic review","volume":"14","author":"Yu AK","year":"2022","unstructured":"Yu AK, Kilic F, Dhawan R, et al.. High-intensity interval training among heart failure patients and heart transplant recipients: a systematic review. Cureus. 2022, 14:e21333. 10.7759\/cureus.21333","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799504786","article-title":"The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis","volume":"18","author":"Peters MJ","year":"2012","unstructured":"Peters MJ, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2012, 18:1502-11. 10.2174\/138161212799504786","journal-title":"Curr Pharm Des"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe C","year":"2011","unstructured":"Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011, 63:522-9. 10.1002\/acr.20371","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq316","article-title":"Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"50","author":"Westlake SL","year":"2011","unstructured":"Westlake SL, Colebatch AN, Baird J, et al.. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011, 50:518-31. 10.1093\/rheumatology\/keq316","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.014","article-title":"Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues","volume":"10","author":"Cacciapaglia F","year":"2011","unstructured":"Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev. 2011, 10:631-5. 10.1016\/j.autrev.2011.04.014","journal-title":"Autoimmun Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155742","article-title":"Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints","volume":"149","author":"Jarlborg M","year":"2022","unstructured":"Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022, 149:155742. 10.1016\/j.cyto.2021.155742","journal-title":"Cytokine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2003.09.004","article-title":"Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers","volume":"3","author":"Ferraccioli G","year":"2004","unstructured":"Ferraccioli G, Gremese E. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. Autoimmun Rev. 2004, 3:261-6. 10.1016\/j.autrev.2003.09.004","journal-title":"Autoimmun Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.219","article-title":"Vascular effects of biologic agents in RA and spondyloarthropathies","volume":"5","author":"Szekanecz Z","year":"2009","unstructured":"Szekanecz Z, Kerekes G, Solt\u00e9sz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009, 5:677-84. 10.1038\/nrrheum.2009.219","journal-title":"Nat Rev Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem033","article-title":"A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases","volume":"46","author":"Weisman MH","year":"2007","unstructured":"Weisman MH, Paulus HE, Burch FX, et al.. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford). 2007, 46:1122-5. 10.1093\/rheumatology\/kem033","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles JT","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S, et al.. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020, 72:31-40. 10.1002\/art.41095","journal-title":"Arthritis Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.016","article-title":"Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs","volume":"126","author":"Solomon DH","year":"2013","unstructured":"Solomon DH, Curtis JR, Saag KG, et al.. Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs. Am J Med. 2013, 126:730.e9-17. 10.1016\/j.amjmed.2013.02.016","journal-title":"Am J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis","volume":"156","author":"Setoguchi S","year":"2008","unstructured":"Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008, 156:336-41. 10.1016\/j.ahj.2008.02.025","journal-title":"Am Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2010.09.005","article-title":"Tumor necrosis factor-\u03b1 blockade, cardiovascular outcomes, and survival in rheumatoid arthritis","volume":"157","author":"Al-Aly Z","year":"2011","unstructured":"Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, Eisen S. Tumor necrosis factor-\u03b1 blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res. 2011, 157:10-8. 10.1016\/j.trsl.2010.09.005","journal-title":"Transl Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22166","article-title":"Tumor necrosis factor \u03b1 inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis","volume":"66","author":"Bili A","year":"2014","unstructured":"Bili A, Tang X, Pranesh S, et al.. Tumor necrosis factor \u03b1 inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014, 66:355-63. 10.1002\/acr.22166","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131464","article-title":"Tumor necrosis factor-\u03b1 inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study","volume":"41","author":"Desai RJ","year":"2014","unstructured":"Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J. Tumor necrosis factor-\u03b1 inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol. 2014, 41:2129-36. 10.3899\/jrheum.131464","journal-title":"J Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon WG","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007, 56:2905-12. 10.1002\/art.22809","journal-title":"Arthritis Rheum"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170926","article-title":"Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease","volume":"45","author":"Jin Y","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018, 45:1240-8. 10.3899\/jrheum.170926","journal-title":"J Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007393","article-title":"Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study","volume":"7","author":"Kang EH","year":"2018","unstructured":"Kang EH, Jin Y, Brill G, Lewey J, Patorno E, Desai RJ, Kim SC. Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc. 2018, 7:e007393. 10.1161\/JAHA.117.007393","journal-title":"J Am Heart Assoc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/art.39582","article-title":"Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis","volume":"68","author":"Low AS","year":"2016","unstructured":"Low AS, Lunt M, Mercer LK, Watson KD, Dixon WG, Symmons DP, Hyrich KL. Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016, 68:1337-45. 10.1002\/art.39582","journal-title":"Arthritis Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low AS","year":"2017","unstructured":"Low AS, Symmons DP, Lunt M, et al.. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017, 76:654-60. 10.1136\/annrheumdis-2016-209784","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0272-4","article-title":"Managing macrophages in rheumatoid arthritis by reform or removal","volume":"14","author":"Li J","year":"2012","unstructured":"Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep. 2012, 14:445-54. 10.1007\/s11926-012-0272-4","journal-title":"Curr Rheumatol Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem202","article-title":"Systemic inflammation as a risk factor for atherothrombosis","volume":"47","author":"van Leuven SI","year":"2008","unstructured":"van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2008, 47:3-7. 10.1093\/rheumatology\/kem202","journal-title":"Rheumatology (Oxford)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.220427097","article-title":"Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model","volume":"97","author":"Ludewig B","year":"2000","unstructured":"Ludewig B, Freigang S, J\u00e4ggi M, et al.. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A. 2000, 97:12752-7. 10.1073\/pnas.220427097","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken198","article-title":"Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease","volume":"47","author":"Mathieu S","year":"2008","unstructured":"Mathieu S, Joly H, Baron G, et al.. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008, 47:1203-7. 10.1093\/rheumatology\/ken198","journal-title":"Rheumatology (Oxford)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086157","article-title":"Infliximab improves vascular stiffness in patients with rheumatoid arthritis","volume":"68","author":"Wong M","year":"2009","unstructured":"Wong M, Oakley SP, Young L, et al.. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2009, 68:1277-84. 10.1136\/ard.2007.086157","journal-title":"Ann Rheum Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0803-y","article-title":"TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis","volume":"27","author":"Bosello S","year":"2008","unstructured":"Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol. 2008, 27:833-9. 10.1007\/s10067-007-0803-y","journal-title":"Clin Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701633238","article-title":"Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis","volume":"37","author":"W\u00e5llberg-Jonsson S","year":"2008","unstructured":"W\u00e5llberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantap\u00e4\u00e4-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol. 2008, 37:1-5. 10.1080\/03009740701633238","journal-title":"Scand J Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000037521.71373.44","article-title":"Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis","volume":"106","author":"H\u00fcrlimann D","year":"2002","unstructured":"H\u00fcrlimann D, Forster A, Noll G, et al.. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002, 106:2184-7. 10.1161\/01.cir.0000037521.71373.44","journal-title":"Circulation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802403713","article-title":"Anti-inflammatory and anti-atherogenic effects of adiponectin in patients with rheumatoid arthritis following anti-TNF therapy","volume":"38","author":"Kapoor S","year":"2009","unstructured":"Kapoor S. Anti-inflammatory and anti-atherogenic effects of adiponectin in patients with rheumatoid arthritis following anti-TNF therapy. Scand J Rheumatol. 2009, 38:158. 10.1080\/03009740802403713","journal-title":"Scand J Rheumatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0632-2","article-title":"Cardiovascular risk in patients with rheumatoid arthritis","volume":"39","author":"Lauper K","year":"2017","unstructured":"Lauper K, Gabay C. Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol. 2017, 39:447-59. 10.1007\/s00281-017-0632-2","journal-title":"Semin Immunopathol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n I","year":"2014","unstructured":"del Rinc\u00f3n I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014, 66:264-72. 10.1002\/art.38210","journal-title":"Arthritis Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.07.012","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication","volume":"50","author":"Braun J","year":"2020","unstructured":"Braun J, Baraliakos X, Westhoff T. Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. Semin Arthritis Rheum. 2020, 50:285-8. 10.1016\/j.semarthrit.2019.07.012","journal-title":"Semin Arthritis Rheum"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/art.24390","article-title":"Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis","volume":"61","author":"L\u00f3pez-Longo FJ","year":"2009","unstructured":"L\u00f3pez-Longo FJ, Oliver-Mi\u00f1arro D, de la Torre I, et al.. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009, 61:419-24. 10.1002\/art.24390","journal-title":"Arthritis Rheum"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/art.10419","article-title":"Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients","volume":"46","author":"Goodson NJ","year":"2002","unstructured":"Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002, 46:2010-9. 10.1002\/art.10419","journal-title":"Arthritis Rheum"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2011.585350","article-title":"Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients","volume":"40","author":"Hjeltnes G","year":"2011","unstructured":"Hjeltnes G, Hollan I, F\u00f8rre \u00d8, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients. Scand J Rheumatol. 2011, 40:422-7. 10.3109\/03009742.2011.585350","journal-title":"Scand J Rheumatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23567","article-title":"Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis","volume":"70","author":"Lauper K","year":"2018","unstructured":"Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C. Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res (Hoboken). 2018, 70:1756-63. 10.1002\/acr.23567","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"Skeoch S","year":"2015","unstructured":"Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nat Rev Rheumatol. 2015, 11:390-400. 10.1038\/nrrheum.2015.40","journal-title":"Nat Rev Rheumatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.2002.1533","article-title":"Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection","volume":"34","author":"Lecour S","year":"2002","unstructured":"Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002, 34:509-18. 10.1006\/jmcc.2002.1533","journal-title":"J Mol Cell Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.74.5.1124","article-title":"Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium","volume":"74","author":"Murry CE","year":"1986","unstructured":"Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986, 74:1124-36. 10.1161\/01.cir.74.5.1124","journal-title":"Circulation"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(00)00058-9","article-title":"Ischemic preconditioning: from basic mechanisms to clinical applications","volume":"86","author":"Nakano A","year":"2000","unstructured":"Nakano A, Cohen MV, Downey JM. Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther. 2000, 86:263-75. 10.1016\/s0163-7258(00)00058-9","journal-title":"Pharmacol Ther"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine B","year":"1990","unstructured":"Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990, 323:236-41. 10.1056\/NEJM199007263230405","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00589-7","article-title":"Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"27","author":"Torre-Amione G","year":"1996","unstructured":"Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996, 27:1201-6. 10.1016\/0735-1097(95)00589-7","journal-title":"J Am Coll Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.2.323","article-title":"Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors","volume":"175","author":"Aderka D","year":"1992","unstructured":"Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992, 175:323-9. 10.1084\/jem.175.2.323","journal-title":"J Exp Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon BJ","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995, 7:251-9. 10.1006\/cyto.1995.0029","journal-title":"Cytokine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/93507-tumor-necrosis-factor-alpha-inhibitors-and-cardiovascular-risk-in-rheumatoid-arthritis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:16Z","timestamp":1707508036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/93507-tumor-necrosis-factor-alpha-inhibitors-and-cardiovascular-risk-in-rheumatoid-arthritis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.26430","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}